PartnershipApr 6, 2026, 11:54 AM
NightFood Holdings Enters Joint Development, Manufacturing, and Licensing Agreement with Oncotelic Therapeutics and TechForce Robotics
AI Summary
NightFood Holdings' SEC filing reveals a material agreement between Oncotelic Therapeutics and TechForce Robotics for the joint development, manufacturing, and licensing of integrated AI-enabled, GMP-compliant robotic systems for pharmaceutical manufacturing. This partnership combines Oncotelic's AI platform and pharmaceutical expertise with TechForce's robotics and AI capabilities, potentially creating new revenue streams and market opportunities for all parties involved.
Key Highlights
- Agreement involves joint development, manufacturing, and commercialization of AI-enabled robotic systems.
- Partnership leverages Oncotelic's AI platform and pharmaceutical expertise with TechForce's robotics and AI capabilities.
- Aims to create GMP-compliant robotic systems for use in pharmaceutical manufacturing environments.